Tumor budding study for colorectal cancer
Part of Cancer, Digestive system clinical trials.
This study looks at a feature of colorectal cancer called tumor budding, which may help doctors understand how the cancer behaves. It does not involve new treatments but may provide information that could guide care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with colorectal cancer (carcinoma).
- A tissue sample (biopsy or surgical specimen) from your cancer must be available for testing.
- The tissue sample must be in good condition, not damaged or dead (necrotic).
- Your medical records must have enough information about your case.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a new drug that may help treat colorectal cancer, and also tests a blood marker that could help diagnose it. It is for people who are already scheduled to have their colorectal tumor removed with surgery.
This study measures “minimal residual disease,” meaning tiny amounts of cancer that may remain after surgery, using blood samples. It may help doctors better detect who is at higher risk of cancer coming back and guide follow-up care.
This study looks at tissue samples from people with colorectal cancer to better understand tumor features and how they may respond to treatment. If you have colorectal cancer, the trial may help researchers match future treatments more effectively.
This study looks for blood/tumor signals (“biomarkers”) that may help predict outcomes in people whose colorectal cancer returns and spreads after surgery. It mainly helps researchers understand who may do better or worse, which can guide future care.
This retrospective study uses existing colorectal cancer imaging and/or preserved tissue samples to support more precise (personalized) research. It may help researchers better understand colorectal cancer over time, but it does not involve new treatment.
This study looks at how the immune system reacts to colorectal cancer in the body. It aims to understand immune responses better, which may help improve future treatments.
Hear when a new Colorectal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.